At Pathalys Pharma, Inc. we are committed to improving the lives of patients through the development of enhanced therapeutics that improve the management of chronic kidney disease (CKD).
Pathalys is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of late stage chronic kidney disease (CKD).
THE PROBLEM
While advancements have been made, many critical unmet needs remain. For Pathalys, these unmet needs are our call-to-action.
One such unmet need and an initial area of focus for Pathalys is the improved treatment for secondary hyperparathyroidism (SHPT). SHPT is a condition in which a disease outside of the parathyroid glands causes all the parathyroid glands to become enlarged and hyperactive, overproducing parathyroid hormone (PTH).
The most common causes of SHPT are kidney failure and vitamin D deficiency. In kidney failure, the kidney is no longer able to make enough vitamin D or remove all the phosphorus that is made by the body, which leads to low calcium levels.
These low calcium levels stimulate the parathyroid glands to make more PTH. Over time, this constant stimulation causes the parathyroid glands to grow and become hyperactive and patients can progress to develop SHPT.1
THE SOLUTION
Upacicalcet is a novel calcimimetic that can be delivered intravenously at the end of the hemodialysis session via pre-filled syringe and has been demonstrated to effectively reduce levels of PTH and may have a better tolerability profile for patients.
Beyond upacicalcet, Pathalys continues to identify high priority needs and potential solutions for patients with end-stage kidney disease.
Note: Upacicalcet is an investigational product candidate in the United States and subject to regulatory review and approval by the U.S. Food and Drug Administration (FDA).
Oversubscribed Financing Paves Path to NDA Submission and Pre-commercialization Efforts for upacicalcet RESEARCH TRIANGLE PARK, NC – August 20, 2024 – Pathalys Pharma, Inc., a private biopharmaceutical company in the late stages of developing treatments for kidney disease, has successfully
RESEARCH TRIANGLE PARK, NC — August 13, 2024 – Pathalys Pharma, Inc., a private biopharmaceutical company in the late stages of developing treatments for kidney disease, today announced it has appointed Bastian Dehmel, M.D. as its Chief Medical Officer. In
Pathalys and LaunchTx leverage recently announced collaboration to accelerate enrollment for the upacicalcet development program. Research Triangle Park, North Carolina and Boston, Massachusetts, May 31, 2023 – Pathalys Pharma, Inc., a private, late-stage biopharma company co-founded by Catalys Pacific and DaVita Venture Group, and